Market research
ITCI Intracellular Th
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 14B
- P/E ratio
- Not available
- Analyst target
- 132
- Dividend yield
- Not available
- Beta
- 0.46
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- US46116X1019
- Market cap
- 14B
- P/E ratio
- Not available
- Analyst target
- 132
- Dividend yield
- Not available
- Beta
- 0.46
About
About Intracellular Th
Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company that develops and commercializes therapeutics and small molecule drugs for central nervous system (CNS), neuropsychiatric, and neurological disorders. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It distributes its products through third-party wholesale drug distributors. The company was founded in 2002 and is based in Bedminster, New Jersey. As of April 2, 2025, Intra-Cellular Therapies, Inc. operates as a subsidiary of Johnson & Johnson Innovative Medicine.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the ITCI discussion.
5 years, 4 months ago
Intra-Cellular Therapies, Inc is currently in a long term uptrend where the price is trading 28.4% above its 200 day moving average.
From a valuation standpoint, the stock is 92.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 101.4.
Intra-Cellular Therapies, Inc's total revenue rose by 20447.2% to $12M since the same quarter in the previous year.
Its net income has increased by 99.9% to $-61K since the same quarter in the previous year.
Finally, its free cash flow fell by 91.3% to $-68M since the same quarter in the previous year.
Based on the above factors, Intra-Cellular Therapies, Inc gets an overall score of 4/5.